The Lancet’s Post

Antibiotic resistance problem is real!! Lets help to preserve one on the most precious jewels of the modern medicine.

Important read on #antimicrobialresistance and the cost of inaction on this global threat to public health. 🚨🦠 "An economic study commissioned for the report projected that by 2035, without substantial action on AMR, global life expectancy would drop by 1·8 years..."

Antimicrobial resistance (AMR) is a growing public health problem that affects health, the economy, and human development. A 2016 review of AMR showed that drug-resistant infections will kill 10 million persons annually by 2050 and cause a cumulative economic loss of US $100 trillion if proactive solutions to slow the rise of drug resistance are not implemented. Although some persons have criticized this forecast, numerous researchers agree that the spread of AMR is an urgent problem, one that will require a global, coordinated action plan to solve. Recently, a study using statistical predictive models based on a comprehensive systematic review estimated 4.95 million deaths related to AMR, including 1.27 million deaths attributable to AMR, occurred across 204 countries and territories in 2019. The highest burden of AMR is seen in low-resource settings. AMR was the third leading underlying cause of death for 2019 in the Institute for Health Metrics and Evaluation’s Global Burden of Disease study

NEW REPORT: Every year, antimicrobial resistance (AMR) directly causes 1.27 million deaths, with low- and middle-income countries accounting for nearly 90% of the direct death toll. We are delighted to support the publication of Center for Global Development's report, "A New Grand Bargain to Improve the Antimicrobial Market for Human Health," launched alongside this year's UN General Assembly. The report amplifies the voices of experts and advocates across the Global South and advances the conversation on how novel procurement systems for health commodities can facilitate access, stewardship, and innovation across LMICs. Read the report at the link in comments. CII's Elijah Kahn-Woods is honored to be acknowledged for his contributions to this report and is eager to leverage the great work of authors Anthony McDonnell, Javier Guzman, and others at CGD in hopes of translating their findings into practical, implementable solutions to our global antimicrobial resistance crisis. Reach out or stay tuned for updates on how CII is employing market shaping and innovative financing tools to improve access to diagnostics and antimicrobials while promoting their appropriate use!

🦠NEW #AntimicrobialResistance (AMR) research done in partnership with University of Oxford, Fleming Fund, Wellcome Trust, Bill & Melinda Gates Foundation, we found that AMR is a significant threat in all 35 countries in the Americas and was involved in 569K deaths in the region in 2019 (more than 43% of infection-related deaths), constituting 11.5% of all global deaths associated with AMR. https://bit.ly/3OITxcl 💡What? In the Americas, among the deadliest Infectious syndromes were: - lower respiratory infections - bloodstream infections - intra-abdominal infections - urinary tract infections (# UTIs) 💡Where? Country in the Americas with the highest mortality rates associated with AMR: Haiti; while the lowest was Canada 💡Age? Death rates caused by AMR had a similar pattern across countries based on age; newborns had high death rates while children under 5 had almost no deaths from AMR. The death rates slowly increased until around age 65, when they dramatically rose. Interested in learning more? Check out our following related research, tools, and event: - Global burden of bacterial AMR estimates: https://bit.ly/3Ojif1q - Interactive Visualization data tool on AMR: https://bit.ly/3DLK2CT - You can learn more about AMR in the Americas & more from us at the AMR Congress panel session titled “An Emerging Threat: AMR Burden at the Country Level” in Philadelphia, September 8: https://bit.ly/3KyIaBs

Many people do not know this about Antimicrobial Resistance (AMR) The rise of antimicrobial resistance is a pressing global issue that demands our attention and collective action. You may be wondering, how does AMR occur?,...AMR occurs when bacteria, viruses, fungi, and parasites evolve and become resistant to the medications designed to treat them. This not only poses a threat to public health but also undermines the effectiveness of our medical treatments. Why is AMR a concern? Reduced effectiveness of antibiotics Prolonged illnesses and increased mortality rates Higher healthcare costs and resource strain. It is predicted that by the year 2050 there will be an additional US$ 1 trillion to the healthcare costs due to AMR What can we do? Raise awareness: Share this post and spread the word about #AMR. Responsible antibiotic use: Only take antibiotics prescribed by healthcare professionals. Support research: Encourage and participate in studies addressing AMR. Let's join forces to combat antimicrobial resistance! 💪 Together, we can make a difference in safeguarding the effectiveness of crucial medications. I am a Medical microbiologist, a researcher, a health writer and I also share educational content here. #AMRAwareness #PublicHealth #GlobalHealth #AntibioticResistance

PDF The Development Dimension Coherence for Health : Innovation for New Medicines for Infectious Diseases. OECD digsell https://lnkd.in/e8JfP4_Y In developing countries, 6 out of 10 people die from infectious diseases. Nearly 1 billion humans suffer from a neglected infectious disease, according to the World Health Organisation. Yet less than 1% of the new drugs placed on the market from 1975 to the turn of the century were developed for these diseases. This book looks at ways of improving the availability of medicines for infectious diseases through strengthened coherence in health, trade, science and technology, development co-operation and finance.  Read more… https://lnkd.in/eCxT_jUg

🌍 Join us virtually for the premiere of the 2024 The Lancet series on #AMR! The global fight for better health outcomes and decades of progress in treating infections are at risk due to antimicrobial resistance (AMR). The United Nations General Assembly (UNGA) will hold a high-level meeting in September 2024 to discuss this present and growing threat. To bolster the momentum gained from this watershed moment in the battle to control AMR, a Lancet series was commissioned to provide crucial data, evidence, and policy recommendations to serve as the cornerstone for a U.N. resolution addressing AMR. In the series, we touch on the current burden of AMR, the importance of expanding antibiotic access and innovation, and the need to promote the establishment of global targets and get politicians on board. To commemorate the series, #OneHealthTrust, #FIND,  #IFPMA, #ICARS, #AMRActionFund, #AfricaCDC, GlobalAMR R&D Hub, and #IDSA are holding a symposium, gathering authors, experts, policymakers, and civil society to discuss AMR's impact, the importance of antibiotic access, and the push for global targets. While the in-person event is invitation-only, catch the live stream to be part of this vital conversation! Register here: https://lnkd.in/eN2WPZEP Date and time: May 28, 6:30 PM - 8:30 PM (GMT+2, Geneva, Switzerland)

In this article in Global Public Health, Carolina Rau Steuernagel, Ida Lillehagen and I argue that addressing antimicrobial resistance requires a fundamental re-evaluation of large-scale antibiotic use and production and propose exploring the inherent complexity and interdependence of AMR issues. Our proposition advocates for alternative futures that foster collaborations between human and non-human actors, ultimately envisioning a shift in human-microbial relationships towards more integrative health strategies. https://lnkd.in/gNeMHMDz

Gareth Morgan, Global Head of Portfolio Management and AMR Policy, took part in a recent AMR Industry Alliance’s meeting on antimicrobial resistance (#AMR). United Nations Member State representatives and AMR stakeholders convened to review priority actions needed to address this urgent public health threat in advance of the UN High Level Meeting (HLM), taking place this September. The HLM is an important opportunity for governments, international organizations, academia, civil society and industry to align on priorities and for the UN to approve an action-oriented political declaration to address AMR.  At the meeting, AMR Industry Alliance launched the industry’s “Call-to-Action” encouraging the UN Member States to commit to and advance bold, coordinated action on AMR. The meeting included panel discussions about repairing the market for antimicrobials, the importance of diagnostics, overcoming barriers to equitable access and strengthening responsible manufacturing. Gareth spoke about our work with Global Antibiotic R&D Partnership (GARDP) and Clinton Health Access Initiative, Inc. to address AMR.    Read more about the Alliance's call-to-action here: https://bit.ly/3V0gcVh